Physician profile
Jayashree Joshi
NPI 1720066426
$5,963.24
in general payments reported to CMS, 2019-2025
28 companies · $437 in 2025
The $437 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,064 · 2020: $737 · 2021: $826 · 2022: $1,171 · 2023: $1,097 · 2024: $633 · 2025: $437.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,167.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,166.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,028.60 | 2019-2024 | Breztri, Fasenra, Airsupra |
| Glaxosmithkline, LLC. | $691.29 | 2020-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Novo Nordisk INC | $462.80 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Abbott Laboratories | $408.64 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Redhill Biopharma INC. | $401.69 | 2020-2023 | Talicia, Aemcolo, Movantik |
| Bayer Healthcare Pharmaceuticals INC. | $395.94 | 2022-2024 | |
| Lilly USA, LLC | $371.81 | 2019-2024 | Mounjaro |
| Amarin Pharma, INC. | $309.03 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $275.25 | 2019-2021 | |
| Ibsa Pharma INC. | $269.74 | 2022-2025 | Tirosint, Licart, Tirosint |
| Boehringer Ingelheim Pharmaceuticals, INC. | $241.41 | 2019-2024 | Jardiance |
| Janssen Pharmaceuticals, INC | $235.37 | 2019 | |
| Amgen INC. | $152.12 | 2019-2024 | Repatha, Otezla |
| Abbvie INC. | $145.42 | 2022-2023 | |
| Exact Sciences Corporation | $134.42 | 2024-2025 | Cologuard Collection Kit |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mission Pharmacal Company | $112.89 | 2019 | |
| Dexcom, INC. | $80.68 | 2023-2024 | Dexcom G6 Transmitter |
| Irhythm Technologies, INC. | $44.41 | 2022 | |
| Genentech USA, INC. | $35.67 | 2020 | |
| Gilead Sciences, INC. | $22.90 | 2019 | |
| Dynavax Technologies Corporation | $22.82 | 2024 | Heplisav-B |
| Hologic Sales and Service, LLC | $21.30 | 2019 | |
| Sumitomo Pharma America, INC. | $18.80 | 2023 | Myfembree |
| Arbor Pharmaceuticals, INC. | $18.50 | 2019 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $16.97 | 2022 | |
| Therapeuticsmd, INC. | $16.18 | 2019 | |
| Xeris Pharmaceuticals, INC. | $15.22 | 2023 | Gvoke Hypopen |
| Cmp Pharma, INC. | $13.37 | 2024 | Carospir, Atorvaliq, Norliqva |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jayashree Joshi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.